Neuro and cognitive - PeptideBlog

Neuro and cognitive

Research area

Neuro and cognitive

Compounds studied for effects on cognition, mood, neuroprotection, or nerve signaling -- ranging from nootropics with real human trial data to compounds studied only in animals.

13 entries in this category.

  • 9-ME-BC

    9-Me-BC is a German-developed beta-carboline small molecule, not a peptide, studied in cell culture and rodents for dopaminergic neuron protection and regeneration as a candidate Parkinson's treatment. No human trial exists, and it inhibits monoamine oxidase, a drug class with known interaction risks that have not been characterised for this molecule in people.

  • Cerebrolysin

    Cerebrolysin is a manufactured mixture of peptide fragments and amino acids from enzymatically digested porcine brain tissue, not a single peptide. It has real Western randomized placebo-controlled trials in stroke, Alzheimer's disease and subarachnoid hemorrhage, with mixed results, and no FDA or EMA approval.

  • Cortexin

    Cortexin is a manufactured mixture of polypeptides from young cattle or pig cerebral cortex, a Russian bioregulator drug related in concept to Cerebrolysin. Its human trials are small, Russian-language, and tested it via nasal electrophoresis or combined with breathing exercises, not as a standalone injection against placebo.

  • Dihexa

    Dihexa is an engineered small molecule, not a peptide, developed from angiotensin IV research at Washington State University to activate the HGF/c-Met growth-factor pathway. Every finding is rodent. No human trial of Dihexa itself exists; a related compound, fosgonimeton, was carried into human trials instead.

  • DSIP

    DSIP is a 1977-discovered nonapeptide with genuine, though decades-old, blinded and placebo-controlled human trials. Those trials found modest effects on ACTH but no clean, reproduced sleep-architecture effect in a healthy person, which is a different finding than the compound's name and modern marketing suggest.

  • J-147

    J147 is a Salk Institute-designed curcumin-derivative small molecule, not a peptide, now owned by Abrexa Pharmaceuticals. A human Phase 1 safety trial is complete and a Phase 2 acute-stroke trial is recruiting, but no completed human trial has tested whether it actually works, for any indication.

  • Noopept

    Quick answer: Noopept is a synthetic dipeptide-derived nootropic (ethyl ester of a phenylacetyl-prolylglycine) sold worldwide as a research chemical and, in the United States, as an unregulated dietary-supplement ingredient. It is approved as a prescription medication in Russia under the name Omberacetam for cognitive impairment following brain injury or vascular disease. Human evidence is limited ... <a title="Selank / Semax" class="read-more" href="https://peptideblog.net/blends/selank-semax/" aria-label="Read more about Selank / Semax">Read more</a>

  • P21

    P21 is sold as a BDNF-mimetic, TrkB-agonist research peptide. No PubMed-indexed primary research paper or registered trial describing a compound under this name was located for this entry, and the name collides with the unrelated cell-cycle protein p21 (CDKN1A), which dominates search results.

  • PE-22-28

    PE-22-28 is a French-developed, seven-residue TREK-1 channel inhibitor, a stabilised analogue of the peptide spadin, with antidepressant-like effects shown only in mouse behavioural assays and cultured cells. No human trial of PE-22-28 or spadin exists on ClinicalTrials.gov.

  • Selank

    Selank is a tuftsin-derived heptapeptide, registered as a nootropic and anxiolytic drug in Russia. A search combining Selank with human and clinical trial terms returned no results; every anxiolytic, cognitive and immune finding located for this entry was measured in rats or mice, not in people.

  • Selank / Semax

    Selank / Semax pairs two separately registered Russian nootropic nasal drops from the same research lineage. No study has tested the two together, and Selank on its own has no human trial in the literature searched for this site at all, only rat and mouse pharmacology.

  • Semax

    Semax is a Russian-developed ACTH(4-10) fragment analogue, registered as a nasal-drop nootropic drug in Russia and nowhere else. It has real published human trials in post-stroke rehabilitation, but none is a blinded, placebo-controlled study by Western standards, and none has been independently replicated outside Russia.

  • VIP

    VIP is a real 28-amino-acid human hormone with a one-to-two-minute plasma half-life. Its Western human trials are of engineered long-acting analogues or synthetic copies, for COVID-19 ARDS and pulmonary arterial hypertension, not of periodic self-injection for general immune or wellness use.